Abbott India Ltd

Go Back

Abbott India Ltd

  • Employs over 2,600 people
  • Wide network of 35 distribution points
  • Catering to over 4,500 stockists and 150,000 retail outlets
  • As of September 2014, total assets stood at Rs 787.86 crore (US$ 126.5 million)

Abbott India Ltd is one of India's fastest growing pharmaceutical companies and part of Abbott's Global Pharmaceutical business in India.

Headquartered in Mumbai, Abbott India Ltd, a publicly listed company and a subsidiary of Abbott Laboratories, enjoys strong brand equity in multiple therapeutic categories such as Women's Health, Gastroenterology, Neurology, Thyroid, Diabetes & Urology, Pain Management, Vitamins, Anti-Infectives & other therapy areas.

Abbott India Ltd's success is driven by a combination of a highly competent and motivated commercial team, R&D backed products, aided by strong alliances and partnerships. Abbott India Ltd employs over 2,600 people and reaches customers through a wide network of 35 distribution points, catering to over 4,500 stockists and 150,000 retail outlets.

The company has over 100 employees at a state-of-the-art formulation plant at Verna, Goa. The manufacturing plant is designed to produce high quality, high volume formulations using cost efficient processes and has well equipped laboratories and trained personnel to ensure compliance with international quality standards.

Source: http://www.abbott.co.in/index.html

Abbott India Ltd: A promise for life

2014 Abbott India has reported a sales total income from operations of Rs 588.71 crore (US$ 94.56 million) and a net profit of Rs 63.74 crore (US$ 10.23 million) for the quarter ended September 2014.
2013 Awarded Frost & Sullivan "MNC Pharmaceutical Company of the Year" for the third consecutive year.
2012 Certificate of Marketing excellence from IPHMR in collaboration with CMARC for resurgence in Thyroid market in India.
2010 Abbott India has acquired Piramal's Healthcare Solutions business (Domestic Formulations) for an up-front payment of US$ 2.12 billion and an additional US$ 400 million annually for the next four years.
2009 Abbott has acquired Solvay's pharmaceutical business and the deal is said to be valued at US$ 6.6 billion.

Updated: February, 2015

Pharmaceuticals
India's pharmaceutical sector will touch US$ 45 billion by 2020.
x IBEF : India Brand Equity Foundation